Active, not recruitingPhase 3NCT04657289

A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)

Studying Medullary sponge kidney

Last synced from ClinicalTrials.gov May 12, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Hoffmann-La Roche
Principal Investigator: Clinical Trials
Hoffmann-La Roche
Intervention: Ranibizumab(drug)
Enrollment: 451 target
Eligibility: 50 years · All sexes
Timeline: 2021 – 2027

Study locations (30)

Centro Oftalmologico Dr. Charles S.A., Capital Federal, Argentina
Oftalmos, Capital Federal, Argentina
Grupo Laser Vision, Rosario, Argentina
Eyeclinic Albury Wodonga, Albury, New South Wales, Australia
Eye and Retina Consultants, Hurstville, New South Wales, Australia
Retina Associates Liverpool, Liverpool, New South Wales, Australia
Retina and Macula Specialists, Miranda, New South Wales, Australia
Sydney Eye Hospital, Sydney, New South Wales, Australia
Sydney Retina Clinic and Day Surgery, Sydney, New South Wales, Australia
Queensland Eye Institute, Woolloongabba, Queensland, Australia
Centre For Eye Research Australia, East Melbourne, Victoria, Australia
Retina Specialists Victoria, Rowville, Victoria, Australia
The Lions Eye Institute, Nedlands, Western Australia, Australia
LKH-Univ.Klinikum Graz, Graz, Austria
Medizinische Universitat Wien, Vienna, Austria
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04657289 on ClinicalTrials.gov

Other trials for Medullary sponge kidney

Additional recruiting or active studies for the same condition.

See all trials for Medullary sponge kidney →

← Back to all trials